Literature DB >> 23743656

Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.

François Pierre Combes1, Sylvie Retout, Nicolas Frey, France Mentré.   

Abstract

PURPOSE: When information is sparse, individual parameters derived from a non-linear mixed effects model analysis can shrink to the mean. The objective of this work was to predict individual parameter shrinkage from the Bayesian information matrix (M BF ). We 1) Propose and evaluate an approximation of M BF by First-Order linearization (FO), 2) Explore by simulations the relationship between shrinkage and precision of estimates and 3) Evaluate prediction of shrinkage and individual parameter precision.
METHODS: We approximated M BF using FO. From the shrinkage formula in linear mixed effects models, we derived the predicted shrinkage from M BF . Shrinkage values were generated for parameters of two pharmacokinetic models by varying the structure and the magnitude of the random effect and residual error models as well as the design. We then evaluated the approximation of M BF FO and compared it to Monte-Carlo (MC) simulations. We finally compared expected and observed shrinkage as well as the predicted and estimated Standard Errors (SE) of individual parameters.
RESULTS: M BF FO was similar to M BF MC. Predicted and observed shrinkages were close . Predicted and estimated SE were similar.
CONCLUSIONS: M BF FO enables prediction of shrinkage and SE of individual parameters. It can be used for design optimization.

Mesh:

Year:  2013        PMID: 23743656     DOI: 10.1007/s11095-013-1079-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

2.  Adaptive optimal design for bridging studies with an application to population pharmacokinetic studies.

Authors:  Lee Kien Foo; Stephen Duffull
Journal:  Pharm Res       Date:  2012-02-14       Impact factor: 4.200

3.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

4.  Methods of robust design of nonlinear models with an application to pharmacokinetics.

Authors:  Lee-Kien Foo; Stephen Duffull
Journal:  J Biopharm Stat       Date:  2010-07       Impact factor: 1.051

5.  A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models.

Authors:  Ivelina Gueorguieva; Kayode Ogungbenro; Gordon Graham; Sophie Glatt; Leon Aarons
Journal:  Comput Methods Programs Biomed       Date:  2007-02-09       Impact factor: 5.428

6.  Compound optimal design criteria for nonlinear models.

Authors:  J M McGree; J A Eccleston; S B Duffull
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

7.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

8.  Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.

Authors:  Caroline Bazzoli; Sylvie Retout; France Mentré
Journal:  Comput Methods Programs Biomed       Date:  2009-11-04       Impact factor: 5.428

9.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

10.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

View more
  13 in total

1.  A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.

Authors:  Thu Thuy Nguyen; Henri Bénech; Alain Pruvost; Natacha Lenuzza
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

2.  Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.

Authors:  Natacha Lenuzza; Xavier Duval; Grégory Nicolas; Etienne Thévenot; Sylvie Job; Orianne Videau; Céline Narjoz; Marie-Anne Loriot; Philippe Beaune; Laurent Becquemont; France Mentré; Christian Funck-Brentano; Loubna Alavoine; Philippe Arnaud; Marcel Delaforge; Henri Bénech
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-03       Impact factor: 2.441

3.  Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.

Authors:  Thi Huyen Tram Nguyen; Thu Thuy Nguyen; France Mentré
Journal:  Pharm Res       Date:  2017-06-28       Impact factor: 4.200

4.  Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.

Authors:  Sophie Peigné; Sylvain Fouliard; Sophie Decourcelle; Marylore Chenel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-14       Impact factor: 2.745

5.  MatVPC: A User-Friendly MATLAB-Based Tool for the Simulation and Evaluation of Systems Pharmacology Models.

Authors:  K Biliouris; M Lavielle; M N Trame
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-08-22

6.  Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.

Authors:  F P Combes; S Retout; N Frey; F Mentré
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-04-09

7.  Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.

Authors:  T H T Nguyen; J Guedj; J Yu; M Levi; F Mentré
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-07-17

8.  Largazole pharmacokinetics in rats by LC-MS/MS.

Authors:  Mingming Yu; Lilibeth A Salvador; Sherwin K B Sy; Yufei Tang; Ravi S P Singh; Qi-Yin Chen; Yanxia Liu; Jiyong Hong; Hartmut Derendorf; Hendrik Luesch
Journal:  Mar Drugs       Date:  2014-03-20       Impact factor: 5.118

9.  Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.

Authors:  A Tessier; J Bertrand; M Chenel; E Comets
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14

10.  Inter occasion variability in individual optimal design.

Authors:  Anders N Kristoffersson; Lena E Friberg; Joakim Nyberg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-10-01       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.